Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of PI3K inhibitor BKM120 when
given together with cisplatin and etoposide in treating patients with advanced solid tumors
or small cell lung cancer. Drugs used in chemotherapy, such as cisplatin and etoposide, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing , or by stopping them from spreading. PI3K inhibitor BKM120 may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving PI3K
inhibitor BKM120 with cisplatin and etoposide may kill more tumor cells.